Diana Hide 1, Mar Gil 2, Fernanda Andrade 3, Diana Rafael 4, Imma Raurell 5, Miren Bravo 6, Aurora Barberá 7, Jordi Gracia-Sancho 8, Víctor Vargas 9, Salvador Augustin 10, Joan Genescà 11, Simo Schwartz Jr 12, Maria Martell 13
PMID: 32681987 DOI: 10.1016/j.nano.2020.102267


Chronic liver disease (CLD) has no effective treatments apart from reducing its complications. Simvastatin has been tested as vasoprotective drug in experimental models of CLD showing promising results, but also limiting adverse effects. Two types of Pluronic® carriers loading simvastatin (PM108-simv and PM127-simv) as a drug delivery system were developed to avoid these toxicities while increasing the therapeutic window of simvastatin. PM127-simv showed the highest rates of cell internalization in rat liver sinusoidal endothelial cells (LSECs) and significantly lower toxicity than free simvastatin, improving cell phenotype. The in vivo biodistribution was mainly hepatic with 50% of the injected PM found in the liver. Remarkably, after one week of administration in a model of CLD, PM127-simv demonstrated superior effect than free simvastatin in reducing portal hypertension. Moreover, no signs of toxicity of PM127-simv were detected. Our results indicate that simvastatin targeted delivery to LSEC is a promising therapeutic approach for CLD.

Keywords: Cirrhosis; Drug delivery; Nanoparticles; Statins.

Copyright © 2020 Elsevier Inc. All rights reserved.